GLP-1s are the main reason why pharmacy expenditures have reached double digits in 2025, a continuing trend from 2024, ...

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Key research pitching the drugs against each other found Mounjaro was superior when it came to shedding pounds and losing ...

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

The lawsuits come amid several recent studies showing a link between vision complications and people taking drugs ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...